๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Coloplast A/S (CPH:COLO.B)
Denmark flag Denmark ยท Delayed Price ยท Currency is DKK
505.60
+6.10 (1.22%)
Nov 20, 2026, 11:34 AM CET

Coloplast Earnings Call Transcripts

Fiscal Year 2026

  • Q4 25/26

    FY organic growth was 6%, with constant-currency EBIT growth of 4%, while a Kerecis impairment weighed on reported results. Guidance targets 5%-7% annual growth and a mid-20s EBIT margin, alongside increased investment in innovation and U.S. growth.

  • Q3 25/26

    Q3 saw 6% organic revenue growth and 5% EBIT growth in constant currencies, with strong performance in Chronic Care and Interventional Urology, while Biologics faced headwinds from U.S. reimbursement changes. Guidance for the year remains unchanged, with continued focus on U.S. expansion, innovation, and disciplined capital allocation.

  • Q2 25/26

    Solid H1 growth driven by core segments, but Wound & Tissue Repair and Biologics face headwinds from U.S. reimbursement changes and weak China demand. Currency and raw material inflation are expected to pressure margins, but guidance remains for 5%-6% organic growth and 5% EBIT growth.

  • Guidance

    Guidance for FY 2025/2026 was revised down due to Kerecis market challenges and currency headwinds, with organic growth now expected at 5%-6%. Chronic Care and Interventional Urology remain strong, while European wound dressings face pricing pressures.

  • Q1 25/26

    Q1 delivered 6% organic revenue growth and 3% EBIT growth in constant currencies, with strong performance in Interventional Urology and ongoing challenges in Kerecis due to Medicare changes. Full-year guidance is maintained, with Kerecis' margin expected to recover and net profit to rise year-over-year.

Fiscal Year 2025

  • AGM 2025

    The AGM reviewed solid financial results, a new Impact4 strategy, and leadership transitions. Shareholders approved all proposals, including a higher dividend and updated remuneration policy, while management addressed market challenges, supply chain risks, and sustainability goals.

  • Q4 24/25

    Organic growth reached 7% with a 28% EBIT margin before special items, driven by strong chronic care but offset by product recalls and market volatility in other segments. Guidance for 2025-2026 targets 7% organic growth and improved profitability, with continued investment in innovation and efficiency.

  • CMD 2025

    A new five-year strategy targets 7%-8% organic growth, over 20% ROIC, and enhanced customer-centricity, with major investments in technology, efficiency, and sustainability. Chronic Care and Wound & Tissue Repair are key growth drivers, while China and pricing remain challenges.

  • Q3 24/25

    Organic revenue grew 7% with stable EBIT margin, driven by strong chronic care and Kerecis growth, despite headwinds from product returns in China and FX. New strategy and reorganization aim to boost innovation and value creation, with full-year guidance reaffirmed.

  • Q2 24/25

    Organic growth slowed to 6% in H1, prompting a CEO change and revised guidance. Product recalls and China weakness impacted results, but acquisitions and innovation are performing well. New strategy and financial targets will be unveiled in September.

  • Q1 24/25

    Q1 delivered 8% organic growth and a 27% EBIT margin before special items, with strong performance in Chronic Care, Voice and Respiratory, and Advanced Wound Care. Guidance for FY 2024/25 remains at 8%-9% organic growth and 28% EBIT margin, despite product recall and regulatory delays.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Fiscal Year 2017

Fiscal Year 2016

Fiscal Year 2015

Fiscal Year 2014

Fiscal Year 2013

Fiscal Year 2012

Fiscal Year 2011